Journal of the American Academy of Dermatology
Volume 54, Issue 4 , Pages 709-711 , April 2006

Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners

  • Mandeep Kaur, MD

      Affiliations

    • From the Center for Dermatology Research, Departments of Dermatology
    • ,
  • Anthony Liguori, PhD

      Affiliations

    • Physiology/Pharmacology
    • ,
  • Wei Lang, PhD

      Affiliations

    • Public Health Sciences
    • ,
  • Stephen R. Rapp, PhD

      Affiliations

    • Public Health Sciences
    • Psychiatry and Behavioral Medicine
    • ,
  • Alan B. Fleischer Jr., MD

      Affiliations

    • From the Center for Dermatology Research, Departments of Dermatology
    • ,
  • Steven R. Feldman, MD, PhD

      Affiliations

    • From the Center for Dermatology Research, Departments of Dermatology
    • Public Health Sciences
    • Pathology, Wake Forest University School of Medicine
    • Corresponding Author InformationReprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071.

References 

  1. Feldman SR, Liguori A, Kucenic M, Rapp SR, Fleischer AB, Lang W, et al. UV exposure is a reinforcing stimulus in frequent indoor tanners. J Am Acad Dermatol. 2004;51:45–51
  2. Scerra C. Addicted to the sun? Dermatology Times, September 1, 2003. Available at: http://www.dermatologytimes.com/dermatologytimes/article/articleDetail.jsp?id=69605. Accessed January 18, 2006.
  3. Levins PC, Carr DB, Fisher JE, Momtaz K, Parrish JA. Plasma beta-endorphin and beta-lipoprotein response to ultraviolet radiation. [letter] Lancet. 1983;2:166
  4. Kaur M, Liguori A, Fleischer AB, Feldman S. Side effects of naltrexone observed in 2 of 3 frequent tanners: Could frequent tanners have chronically high opioid levels?. J Am Acad Dermatol. 2005;52:916
  5. Perez-Reyes M, Wall ME. A comparative study of the oral, intravenous, and subcutaneous administration of H-Naltrexone to normal male volunteers. Naltrexone: Research Monograph 28. In:  Willette RE,  Barnett G editor. Bethesda (MD): National Institute on Drug Abuse; 1980;p. 93–101Available at: http://www.drugabuse.gov/pdf/monographs/28.pdf. Accessed January 18, 2006
  6. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192–213

 Funding sources: The Center for Dermatology Research is supported by a grant from Galderma Laboratories, L.P. This study was supported by a grant from the National Institutes of Health (DA14014-01) and by a pilot grant from the Wake Forest University Women's Health Center of Excellence.Conflicts of interest: None identified.

PII: S0190-9622(05)04601-3

doi: 10.1016/j.jaad.2005.11.1059

Journal of the American Academy of Dermatology
Volume 54, Issue 4 , Pages 709-711 , April 2006

Article Tools

* Image Usage & Resolution